NYSE:HAE

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Retrieved on: 
Mercredi, avril 10, 2024
HAE, Haemonetics, Conference, Webcast, PIN, Broadcasting

BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024.

Key Points: 
  • BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024.
  • The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024.
  • The call can be accessed via teleconference at: Q4 2024 Haemonetics Corporation Earnings Conference Call.
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

Retrieved on: 
Jeudi, avril 4, 2024
6S, Heparinoid, Patient, HAE, Liver transplantation, MD, Senior, Hemostasis, Heparin, Cardiopulmonary bypass, Safety, FDA, TEG, Physician, Food, Medical device

This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings.

Key Points: 
  • This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings.
  • Haemonetics is planning to release the new Global Hemostasis-HN cartridge for TEG 6s system in the coming months.
  • Overall, over 5,500 clinical data points were used to demonstrate safety and effectiveness of the Global Hemostasis – HN assays.
  • "Our market-leading TEG 6s platform has helped Haemonetics make effective and efficient viscoelastic testing more accessible throughout the world," said Stewart Strong, President, Global Hospital at Haemonetics.

Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

Retrieved on: 
Mercredi, février 21, 2024
Haemonetics, HAE, Conference

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m.

Key Points: 
  • BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m.
  • ET.
  • The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj129/hae/1445840 .
  • A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Retrieved on: 
Mercredi, février 21, 2024
Citigroup, Haemonetics, HAE

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m.

Key Points: 
  • BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m.
  • ET.
  • The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://kvgo.com/unplugged-medtech-life-sciences-access-day/haemonetics-... .
  • A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

Retrieved on: 
Jeudi, janvier 11, 2024
HAE, Haemonetics, Conference, PIN, Webcast, Broadcasting

BOSTON, Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024.

Key Points: 
  • BOSTON, Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024.
  • The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 8, 2024.
  • The call can be accessed via teleconference at: Q3 2024 Haemonetics Corporation Earnings Conference Call .
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

Haemonetics Corporation Completes Acquisition of OpSens Inc.

Retrieved on: 
Mardi, décembre 12, 2023
TAVR, EBITDA, FFR, Pressure, Acquisition, NYSE, OTCQX, Fractional flow reserve, Toronto Stock Exchange, CAD, Patient, Workflow, Coronary artery disease, GAAP, Diagnosis, Growth, Physician, Hospital, DPR, Medical imaging, Haemonetics

"Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.

Key Points: 
  • "Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.
  • "We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world."
  • Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million draw under its revolving credit facility.
  • Following this acquisition, Haemonetics estimates that its net debt to EBITDA ratio, as defined in Haemonetics' existing credit agreement, will be approximately 2.3x.

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Jeudi, décembre 7, 2023
Event, NYSE, Conference, HAE

BOSTON, Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.

Key Points: 
  • BOSTON, Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.
  • The public may access Mr. Simon's presentation live via audio webcast at:
    The live webcast can also be accessed under the Events & Presentations section of the Company's Investor Relations website.
  • The replay of the presentation will be available for 30 days using the link provided above and on Investor Relations website shortly after the live event.

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

Retrieved on: 
Mardi, octobre 10, 2023
Pressure, Diagnosis, Hospital, Physician, NYSE, TSX, Acquisition, FFR, Model Business Corporation Act, Piper, Fractional flow reserve, EBITDA, PCI, HVS Global Hospitality Services, TAVR, DLA, DPR, Workflow, Credit agreements in South Africa, DLA Piper, CAD, Growth, Goldman Sachs, Vascular closure device, GAAP, Patient, Coronary artery disease, Pharmaceutical industry, Medical imaging, Fine chemical, Bank, Haemonetics

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

Key Points: 
  • OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.
  • Stewart Strong, President, Global Hospital at Haemonetics, said, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification.
  • Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x.
  • Haemonetics posted supplemental slides with additional information about this transaction to Haemonetics' investor relations website.

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023

Retrieved on: 
Jeudi, octobre 5, 2023
PIN, NYSE, Haemonetics, Webcast, HAE, Conference, Pharmaceutical industry, Broadcasting

BOSTON, Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.

Key Points: 
  • BOSTON, Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.
  • The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 2, 2023.
  • The call can be accessed via teleconference at: Q2 2024 Haemonetics Corporation Earnings Conference Call .
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

Haemonetics Announces European Expansion for VASCADE® Vascular Closure System

Retrieved on: 
Mardi, août 29, 2023
CE, EU, International, Gleneagles Global Hospitals, HAE, Back pain, Jewish Hospital (Cincinnati, Ohio), Hospital, Hemostasis, Cardiac catheterization, Medical director, Patient, Physician, Cardiology, EP, Haemonetics, MVP, European Medical Students' Association, NYSE, Pharmaceutical industry, Medical imaging, Electrophysiology

This marks the first use of the VASCADE system portfolio, widely used in U.S. hospitals, in a European country.

Key Points: 
  • This marks the first use of the VASCADE system portfolio, widely used in U.S. hospitals, in a European country.
  • The VASCADE system is designed for "small-bore" femoral arterial and venous closure, generally used in interventional cardiology and peripheral vascular procedures.
  • The VASCADE MVP system is designed for "mid-bore" multi-access femoral venous closure, generally used in electrophysiology procedures.
  • Haemonetics is planning further expansion for the VASCADE system portfolio in other markets outside the U.S.